November 2016 Newsletter
IASLC Now Accepting Applications for 2017-2018 Lung Cancer Fellowship and Young Investigator Awards
The International Association for the Study of Lung Cancer (IASLC) is proud to announce the annual IASLC Fellowship and Young Investigators Programs.
Applications are requested for the 2017 - 2018 Fellowship and Young Investigator award cycle. Overall, there will be a minimum of three awards of $50,000, each for the duration of one year, with at least one recipient from each region (North America, Europe, and the rest of the world) funded. The funding period will be July 1, 2017 – June 30, 2018.
The goal is to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine. Applications will be evaluated by a Scientific Review Panel for their merit, innovation, and potential impact on the management of lung cancer.
Apply Now. Deadline to apply is January 9, 2017.
November is Lung Cancer Awareness Month
The IASLC-led harmonized public awareness campaign for November's Lung Cancer Awareness Month (LCAM) is now up and running. The campaign features a brand new website focusing on those who've been affected by lung cancer (including patients, family members, and advocates). The site will also point to promising advances in the field of lung cancer treatment and care that are enabling those affected to lead happier, healthier, and longer lives.
The lung cancer community can participate in this initiative during the month of November by submitting personal stories to be included in the site. We encourage you to follow the campaign-specific social media feeds we have established on Facebook and Twitter.
IASLC kicked off the month by hosting a Lung Cancer Awareness Month Forum, which included briefings by industry experts and personal stories by those who have been affected by the disease. This event was held in conjunction with the unveiling of IASLC's newly-expanded office space.
IASLC Board INCREASES the Fellowship Matching Challenge
In September, the IASLC and IASLC Foundation Board Members joined together to create the Fellowship Matching Challenge. Based on the success of the challenge during its early weeks, the Board Members are increasing the matching pot. Between now and December 31, the Board Members will match dollar-for-dollar any new or increased contributions up to $17,500.
As someone who wishes to be better educated about lung cancer, you understand the importance of people working to improve what is currently medically possible.
Since 2000, the IASLC has provided more than 80 researchers with fellowships. Fellowship grants have been awarded to medical doctors and scientists throughout the world, including Italy, the United States, Japan, Spain, Australia, France, China, Denmark, Ireland, Taiwan, Germany, Thailand, Poland, and Canada. We want to continue to grow these opportunities by awarding an increased number of fellowships to encourage even more groundbreaking research and worldwide collaboration.
Take Part in the Latin America Pathology Survey
As part of a project aiming to facilitate the increase of molecular testing to lung cancer patients in Latin American countries, we invite IASLC members from the area and other health care personnel involved or interested in molecular testing for lung cancer to answer this survey.
The results will be presented at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria, which will take place Dec. 4-7. The data will support the development of proposals and strategies that will then be submitted to the IASLC with the intention of helping Latin American laboratories overcome common regional problems.
Your participation is important and assists with understanding regional realities. It will allow us to identify concrete measures to assist labs in their efforts to offer high standard and cost-effective molecular tests.
Meet the JTO Editor!
The Journal of Thoracic Oncology invites IASLC 17th World Conference on Lung Cancer (WCLC) attendees to meet with the Editor-in-Chief, Alex A. Adjei, MD, PhD, and the Managing Editor, Mary Todd.
Learn about manuscript submission, plans for the journal’s future, and provide feedback and suggestions. The session will be held on Monday, December 5 from 14:30-15:45, and it will be held in Room Schubert 4 in the Messe Wien Conference Center.
Academic, Career, and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post opportunities when we receive information from grantors. We currently have five funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Social Media at WCLC 2016
Matthew Evison, Manchester, UK
It's only a month to go until the IASLC 17th World Conference on Lung Cancer (WCLC) in Vienna! The IASLC social media team is busy preparing to help connect IASLC members and conference delegates through social media and spread the latest research and education throughout the lung cancer community. For those attending the conference and those wanting to keep up to date with the latest developments through social media, please use the conference hashtag: #WCLC2016.
We also encourage the use of the Lung Cancer Social Media hashtag #LCSM, a lung cancer community forged on social media and dedicated to education, promotion of awareness, tackling stigma, and highlighting the latest research in lung cancer. For those using social media at WCLC, here is a link to the conference social media policy.
Vienna is known as the city of dreams. During #WCLC2016 we want to hear what your dream is for lung cancer care in the future. Please use the hashtag #MyLungDream. What is my dream? #MyLungDream is for the implementation of worldwide, cost-effective screening that saves many lives from lung cancer!
November 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the November issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
A number of kinase inhibitors in the clinic for the therapy of lung cancer have more than a single protein target. A few compounds are developed as multikinase inhibitors, but the predominant majority are developed against a single target. Thus, alectinib has been developed and approved for use as an ALK kinase inhibitor. Lin et al demonstrate that alectinib is a potent inhibitor of RET kinase.
A Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for Advanced Non-Squamous Non-Small Cell Lung Cancer Including PD-L1 Testing
The cost of oncologic agents has gained attention in the last couple of years with the advent of exorbitantly priced kinase inhibitors and immunologic agents. Matter-Walstra and colleagues present an elegant study on the cost-effectiveness of nivolumab used for the therapy of squamous cell lung cancer in Switzerland. An editorial, Checkpoint Inhibitors in Lung Cancer Are Not Immune From Cost-Effectiveness Analysis, by Ronan Kelly accompanies this article.
Outcome After Post-Operative Radiotherapy (PORT) in ypN2 or R1/R2 Versus No PORT in ypN0 Stage III-N2 Non-Small Cell Lung Cancer After Induction Chemotherapy and Resection
The issue of the utility of post-operative radiotherapy after induction chemotherapy and resection of stage III NSCLC is explored in this article. An editorial, Tri-Modality Approach to Stage IIIA-N2 NCSLC: As Good As it Gets?, by Andrea Bezjak accompanies this article.
The following articles were selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics.
The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.
Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.
Member Discount for IASLC 17th World Conference on Lung Cancer
To find your Member ID in your IASLC account:
1. Login. Enter your Username and Password. If you have forgotten your password, you can reset it with the “Forgot Password” button on your screen. Once signed into your account, click “My Details” on the right side of your screen. You will then see your Member ID appear towards the top of your screen.
2. You will also find your Member ID in any past renewal email notices, invoices, or on your Member ID Card from IASLC. However, please feel free to email email@example.com and we will be happy to provide your Member ID to you right away.
Member Account Information
Free Membership for Patients/Survivors
The IASLC has a free membership option for patients and survivors of any thoracic malignancy. All patients/survivors with a diagnosis of lung cancer, mesothelioma, or other thoracic cancer qualify for this free membership. Patients and survivors can renew this non-voting membership annually. Except for voting, the patient/survivor membership includes all Allied Health Professional member benefits, and includes online access to the JTO, member meeting discounts, eligibility to apply for travel awards, and eligibility to serve on committees. Register as Patient/Survivor.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.